Literature DB >> 9110092

Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals.

Z R Israel, M K Gorny, C Palmer, J A McKeating, S Zolla-Pazner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9110092

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  26 in total

1.  Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Authors:  Miroslaw K Gorny; Ruimin Pan; Constance Williams; Xiao-Hong Wang; Barbara Volsky; Timothy O'Neal; Brett Spurrier; Jared M Sampson; Liuzhe Li; Michael S Seaman; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Virology       Date:  2012-03-07       Impact factor: 3.616

2.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

4.  Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.

Authors:  Rebecca L R Powell; Maxim Totrov; Vincenza Itri; Xiaomei Liu; Alisa Fox; Susan Zolla-Pazner
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

5.  Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.

Authors:  Samantha Townsley; Yun Li; Yury Kozyrev; Brad Cleveland; Shiu-Lok Hu
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

6.  Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.

Authors:  Brett Spurrier; Jared Sampson; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

7.  Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.

Authors:  Ann J Hessell; Mariya B Shapiro; Rebecca Powell; Delphine C Malherbe; Sean P McBurney; Shilpi Pandey; Tracy Cheever; William F Sutton; Christoph Kahl; Byung Park; Susan Zolla-Pazner; Nancy L Haigwood
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 8.  Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Authors:  Susan Zolla-Pazner; Timothy Cardozo
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

9.  Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.

Authors:  Xunqing Jiang; Max Totrov; Wei Li; Jared M Sampson; Constance Williams; Hong Lu; Xueling Wu; Shan Lu; Shixia Wang; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

10.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.